Cequa for Dry eye disease (keratoconjunctivitis sicca)
Quick answer: Cequa is used for Dry eye disease (keratoconjunctivitis sicca) as part of a calcineurin inhibitor (ophthalmic immunomodulator) treatment regimen. Topical ciclosporin nanomicellar solution that inhibits T-cell activation and reduces ocular surface inflammation The specific dosing for Dry eye disease (keratoconjunctivitis sicca) is determined by your prescriber based on individual factors.
Why is Cequa used for Dry eye disease (keratoconjunctivitis sicca)?
Cequa belongs to the Calcineurin inhibitor (ophthalmic immunomodulator) class. Topical ciclosporin nanomicellar solution that inhibits T-cell activation and reduces ocular surface inflammation This action makes it useful for treating or managing Dry eye disease (keratoconjunctivitis sicca) in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Cequa is the right choice for a specific patient depends on the type and severity of Dry eye disease (keratoconjunctivitis sicca), response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Dry eye disease (keratoconjunctivitis sicca)
Common adult dosing range: 1 drop in each eye twice daily. The actual dose for Dry eye disease (keratoconjunctivitis sicca) depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Cequa medicine page.
What to expect
Cequa treatment for Dry eye disease (keratoconjunctivitis sicca) typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Dry eye disease (keratoconjunctivitis sicca)
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Cequa is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Calcineurin inhibitor (ophthalmic immunomodulator) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Cequa
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Cequa full prescribing information · All Calcineurin inhibitor (ophthalmic immunomodulator) alternatives
Frequently asked questions
How effective is Cequa for Dry eye disease (keratoconjunctivitis sicca)?
Effectiveness varies by individual response, dose, and severity. Cequa is one of several treatment options for Dry eye disease (keratoconjunctivitis sicca), supported by clinical evidence within the calcineurin inhibitor (ophthalmic immunomodulator) class. Discuss expected response with your prescriber.
How long do I need to take Cequa for Dry eye disease (keratoconjunctivitis sicca)?
Treatment duration depends on the nature of Dry eye disease (keratoconjunctivitis sicca) — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Cequa when used for Dry eye disease (keratoconjunctivitis sicca)?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Cequa for Dry eye disease (keratoconjunctivitis sicca)?
Yes. Multiple medicines and non-drug options exist for Dry eye disease (keratoconjunctivitis sicca). Alternatives within the calcineurin inhibitor (ophthalmic immunomodulator) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.